CA2787691C — Combinations for use in the inhibition of hiv-1
Assigned to ViiV Healthcare Co · Expires 2018-07-17 · 8y expired
What this patent protects
The present disclosure relates to combinations of compounds comprising HIV integrase inhibitors and other therapeutic agents. Such combinations may be useful in the inhibition of HIV-1 or potentially the inhibition of HIV replication, or for the prevention and/or treatment of inf…
USPTO Abstract
The present disclosure relates to combinations of compounds comprising HIV integrase inhibitors and other therapeutic agents. Such combinations may be useful in the inhibition of HIV-1 or potentially the inhibition of HIV replication, or for the prevention and/or treatment of infection by HIV, or in the treatment of AIDS and/or ARC.
Drugs covered by this patent
Bibliographic data sourced from FDA Orange Book + USPTO public records. Plain-English summary generated by AI grounded in source text. Patent term extensions (PTR, SPC, pediatric) may shift the effective expiry. Not legal advice.
Track this patent
Get a daily-checked alert when vulnerability score, expiry, classification, or assignee changes. Email, Slack, or Teams delivery. Pro: 50 watches, Free: 3.